14 terminated. 14 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Terminated 14 |
| Phase 2 | 4 | Terminated 4 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | Kodiak Sciences Inc | 253 | 2021-09-07 | 2024-09-05 |
| A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention BHV-3500 (zavegepant), Placebo - Migraine | Phase 2 / Phase 3 | Terminated | Pfizer | 1753 | 2021-03-26 | 2025-03-27 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 459 | 2020-09-30 | 2024-08-22 |
| A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 460 | 2020-09-30 | 2024-08-22 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Central Retinal Vein Occlusion | Phase 3 | Terminated | Novartis Pharmaceuticals | 493 | 2019-07-03 | 2023-01-30 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Branch Retinal Vein Occlusion | Phase 3 | Terminated | Novartis Pharmaceuticals | 450 | 2019-07-02 | 2023-01-30 |
| Surgical Idiopathic Intracranial Hypertension Treatment Trial Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting - Idiopathic Intracranial Hypertension | Phase 3 | Terminated | Jaeb Center for Health Research | 7 | 2019-02-06 | 2022-06-16 |
| Cannabis Extract in Refractory Epilepsy Study Medical Cannabis, Placebo - Drug Resistant Epilepsy | Phase 3 | Terminated | The Epilepsy Research Program of the Ontario Brain Institute | 17 | 2019-01-10 | 2020-09-11 |
| Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia Patching, Near activities, Active vision therapy - Amblyopia | Phase 3 | Terminated | Jaeb Center for Health Research | 19 | 2008-04-01 | 2016-07-13 |
| Combined Patching-Atropine for Residual Amblyopia Patching, Atropine - Amblyopia | Phase 3 | Terminated | Jaeb Center for Health Research | 55 | 2007-10-01 | 2016-07-13 |
| Treatment of Refractory Diabetic Macular Edema With Infliximab infliximab, placebo - Diabetic Macular Edema, Visual Acuity | Phase 3 | Terminated | University of Athens | 12 | 2007-07-01 | 2009-02-20 |
Eye Diseases (6) · Retinal Diseases (6) · Macular Edema (5) · Diabetic Retinopathy (4) · Retinal Degeneration (4) · Diabetes Mellitus (3) · Vision, Low (3) · Amblyopia (2) · Eye Abnormalities (2) · Eye Diseases, Hereditary (2) · Macular Degeneration (2) · Retinal Vein Occlusion (2) · Retinitis Pigmentosa (2) · Usher Syndromes (2)
Nervous System Diseases (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Sensation Disorders (14) · Signs and Symptoms (14) · Eye Diseases (8) · Cardiovascular Diseases (6) · Vascular Diseases (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Eye Diseases, Hereditary (5) · Retinal Degeneration (5) · Diabetes Complications (4) · Diabetic Angiopathies (4) · Endocrine System Diseases (4)
aflibercept (5) · salicylhydroxamic acid (3) · Intravitreal Injections (2) · brolucizumab (2) · Acetazolamide (1) · Atropine (1) · Diuretics (1) · Infliximab (1) · Medical Marijuana (1) · Water (1)
Kodiak Sciences Inc (4) · Jaeb Center for Health Research (3) · Laboratoires Thea (2) · Novartis Pharmaceuticals (2) · Pfizer (1) · The Epilepsy Research Program of the Ontario Brain Institute (1) · University of Athens (1)
United States (12) · Puerto Rico (6) · Czechia (5) · Germany (5) · Spain (5) · Canada (4) · Italy (4) · Slovakia (4) · United Kingdom (4) · France (3) · Hungary (3) · Israel (3) · Latvia (3) · Poland (3) · China (2)
Pablo Velazquez-Martin, MD (4) · Daniel Janer, MD (1) · Danielle Andrade, MD (1) · David K. Wallace, M.D. (1) · David T. Wheeler, M.D. (1) · Don W. Lyon, O.D. (1) · Michael Wall, MD (1) · Nancy Mingo, MD (1) · Peter Tai, MD (1) · Petros Sfikakis, MD (1)
PMID 20413522, PMID 21746992, PMID 23563444, PMID 42645743
2018 (2), U10EY011751 (2), U10EY025990 (1)